• Contact us
  • Advertise with us
  • Login
Tashi Pharma
  • Home
  • Indian Pharma News
  • Global Pharma News
  • Guideline News
    • All
    • EDQM
    • EMA
    • European Commision
    • Health Canada
    • Medsafe
    • MHRA
    • SAHPRA
    • US FDA
    FDA Clinical Trial Guidances for Advancing Development of Cancer Treatments

    FDA publishes Clinical Trial Guidances for Advancing Development of Cancer Treatments

    Initiation of Voluntary Recalls Under 21 CFR Part 7, Subpart C

    US FDA publishes guidance on Initiation of Voluntary Recalls

    EMA publishes Q & A for Bootstrap methodology for f2 similarity factor

    EMA publishes Q & A on Bootstrap methodology for f2 similarity factor

    US FDA publishes product-specific guidances to facilitate generic drug development

    US FDA publishes product-specific guidances to facilitate generic drug development

    Clinical Trials Regulation comes into effect in the EU

    New Clinical Trials Regulation comes into effect in the EU

    Reflection paper Forecasting demand for medicinal products in the EU_EEA

    EMA publishes reflection paper on forecasting demand for medicinal products in the EU/EEA

    Trending Tags

    • Pharma
    • EMA
    • MHRA
    • TGA
    • US FDA
  • Articles
  • Interview
  • Company Focus
  • Pharma Jobs
    • Quality
    • Regulatory Affairs
    • Production
    • Sales and Marketing
    • Clinical
    • bioanalytical
  • Webinar
No Result
View All Result
  • Home
  • Indian Pharma News
  • Global Pharma News
  • Guideline News
    • All
    • EDQM
    • EMA
    • European Commision
    • Health Canada
    • Medsafe
    • MHRA
    • SAHPRA
    • US FDA
    FDA Clinical Trial Guidances for Advancing Development of Cancer Treatments

    FDA publishes Clinical Trial Guidances for Advancing Development of Cancer Treatments

    Initiation of Voluntary Recalls Under 21 CFR Part 7, Subpart C

    US FDA publishes guidance on Initiation of Voluntary Recalls

    EMA publishes Q & A for Bootstrap methodology for f2 similarity factor

    EMA publishes Q & A on Bootstrap methodology for f2 similarity factor

    US FDA publishes product-specific guidances to facilitate generic drug development

    US FDA publishes product-specific guidances to facilitate generic drug development

    Clinical Trials Regulation comes into effect in the EU

    New Clinical Trials Regulation comes into effect in the EU

    Reflection paper Forecasting demand for medicinal products in the EU_EEA

    EMA publishes reflection paper on forecasting demand for medicinal products in the EU/EEA

    Trending Tags

    • Pharma
    • EMA
    • MHRA
    • TGA
    • US FDA
  • Articles
  • Interview
  • Company Focus
  • Pharma Jobs
    • Quality
    • Regulatory Affairs
    • Production
    • Sales and Marketing
    • Clinical
    • bioanalytical
  • Webinar
No Result
View All Result
No Result
View All Result
Home Indian Pharma News

Pune-based Startup Ahammune Biosciences raises Pre-Series A funding from Ideaspring Capital and Indian Angel Network

PRN by PRN
April 26, 2021
in Indian Pharma News
41 3
0
29
SHARES
68
VIEWS
  • The Pre-series A funding round was led by Ideaspring Capital and IAN
  • The fresh funds raised will be utilized for “first-in-human” studies with Ahammune’s new drug candidate AB1001 for vitiligo
  • The firm has placed drug candidate as a topical solution, which forms a 54% of the total market share of available options
  • Ahammune Biosciences will also use the funds to build the patent portfolio and to further the research and development efforts of the company

Pune-based biotech startup company, Ahammune Biosciences has raised an undisclosed amount in a Pre-Series A round led by Ideaspring Capital and Indian Angel Network. Kotak Private Equity, Legacy Assets LLP (Baldota family fund), and Dr. Ajith Kamath (ex-Pfizer) have also participated in the round along with existing investors, including Dr. Anand Deshpande and Mr. Suman Kant Munjal. The Company also has Dr. Ganesh Natarajan as an existing investor and has been in receipt of funding grant from Government of India’s body, BIRAC.

The freshly infused capital will be used for “first-in-human” studies with Ahammune’s new drug candidate AB1001 for vitiligo. The study will comprise Phase-I safety studies in healthy human volunteers and Phase-II efficacy studies in vitiligo patients. The biotech company will also deploy the funds in building the patent portfolio to further the research and development efforts.

Vitiligo, a debilitating skin depigmentation disorder, has a global prevalence of about 1-2 percent. The burden of the disease is huge in India with certain regions having an incidence rate of about 8 percent. Ahammune, founded in May 2016, has filed its first Investigational New Drug (IND) Application with the Drug Controller General of India (DCGI) for approval to conduct human studies with its lead drug candidate for vitiligo.

Talking about the latest development, Dr. Parul Ganju, Co-founder and CEO of Ahammune Biosciences said, “Currently, there is no cure for vitiligo. Our drug aims to fulfill the unmet need in Vitiligo therapeutic. We have positioned it as a topical solution, a segment of the market that accounted for 54% of the total market share of available options. Our preclinical data suggest our drug candidate is very safe and is able to stop the spread of depigmentation and repigment white patches in animal models. Based on these studies, the first intended use of the drug will be in patients with non-segmental vitiligo, who have active vitiligo.”

Apart from the treatment for vitiligo, the company is aiming to target multiple dermatological indications with its deep pipeline of IP-based molecules that modulate cellular pathways underlying skin health and immunity.

“This disruptive scientific domain area of Ahammune thus has the potential and huge upside to provide a range of treatments for other immune-mediated diseases of the skin,” added Dr. Ganju.

“Effective Vitiligo treatment is currently an absolute unmet need and an unattended market. Millions of people are suffering because of this disease and lack of available options. There is clearly a tremendous need for a new drug with an upside of huge market potential. In addition to Vitiligo, Ahammune team has the capability to discover drugs for other autoimmune skin disorders like Atopic Dermatitis, Psoriasis, Scleroderma that have an even bigger market. We are very excited to be the first Institutional investor in Ahammune and back stellar founders Dr. Parul and Dr. K. Natarajan,Professor, School of Life Sciences, Jawaharlal Nehru University” said Naganand Doraswamy, MD Ideaspring Capital.

Further commenting, Padmaja Ruparel, Co-Founder at Indian Angel Network said, “Vitiligo is currently an unsolved problem and there is real need for a new drug. This need represents a potential market size of $2.4 billion by the year 2024. Currently, first-line treatments are generic drugs like corticosteroids and immunosuppressants, manufactured by several companies throughout the world. There is really no drug focused on curing vitiligo, which is approved by US-FDA and this presents a unique opportunity for the company. The team of Ahammune, led by Dr. Parul Ganju, has demonstrated a deep understanding of developing the drug and ensuring high level of efficacy”

The company has been founded on the basis of finding cost-effective solutions for chronic skin diseases. Earlier, Ahammune established the efficacy and safety of its drugs in preclinical animal studies and is now transitioning into a clinical phase company. The biotech firm has protected its innovations by filing for IPR, which are its strategic business assets. Since more than 900 million people are affected with skin diseases globally, Ahammune aims to provide patients with new and comprehensive treatment strategies.

Tags: Pharma NewspharmacyPharmareg NewsStart up
Previous Post

Glenmark’s Ryaltris ® nasal spray approved in EU for the first line treatment of allergic rhinitis in patients over 12 years of age

Next Post

Samsung Biologics and TG Therapeutics Expand Collaboration for the Large Scale Manufacture of Ublituximab

PRN

PRN

Related Posts

Zydus to launch Oxemia
Indian Pharma News

Zydus to launch Oxemia (Desidustat) a treatment for Anemia in patients with Chronic Kidney Disease (CKD)

by admin
March 7, 2022
FDA Urges Companies to be 'Recall Ready’ to Protect Public Health as Part of Final Guidance for Voluntary Recalls
Indian Pharma News

US FDA Urges Companies to be ’Recall Ready’ to Protect Public Health

by admin
March 6, 2022
Kilitch Drugs Commences Rs. 100 Crore New Facility Expansion Plan
Indian Pharma News

Kilitch Drugs Commences Rs. 100 Crore New Facility Expansion Plan

by admin
March 5, 2022
Themis Medicare receives approval for immunomodulatory antiviral drug from DCGI
Indian Pharma News

Themis Medicare receives approval for immunomodulatory antiviral drug from DCGI

by admin
March 4, 2022
Lupin Receives Approval from U.S. FDA for Efinaconazole Topical Solution
Indian Pharma News

Lupin Receives Approval from U.S. FDA for Efinaconazole Topical Solution

by admin
March 3, 2022
Next Post
Samsung Biologics and TG Therapeutics Expand Collaboration for the Large Scale Manufacture of Ublituximab

Samsung Biologics and TG Therapeutics Expand Collaboration for the Large Scale Manufacture of Ublituximab

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Recent News

Zydus to launch Oxemia

Zydus to launch Oxemia (Desidustat) a treatment for Anemia in patients with Chronic Kidney Disease (CKD)

March 7, 2022
FDA Urges Companies to be 'Recall Ready’ to Protect Public Health as Part of Final Guidance for Voluntary Recalls

US FDA Urges Companies to be ’Recall Ready’ to Protect Public Health

March 6, 2022
FDA Clinical Trial Guidances for Advancing Development of Cancer Treatments

FDA publishes Clinical Trial Guidances for Advancing Development of Cancer Treatments

March 5, 2022
Initiation of Voluntary Recalls Under 21 CFR Part 7, Subpart C

US FDA publishes guidance on Initiation of Voluntary Recalls

March 5, 2022
Kilitch Drugs Commences Rs. 100 Crore New Facility Expansion Plan

Kilitch Drugs Commences Rs. 100 Crore New Facility Expansion Plan

March 5, 2022

Browse by Category

  • Articles
  • Company Focus
  • EDQM
  • EMA
  • European Commision
  • Global Pharma News
  • Guideline News
  • Health Canada
  • Indian Pharma News
  • Interview
  • Medsafe
  • MHRA
  • SAHPRA
  • US FDA
  • Webinar

Browse by Tags

Abbott Alembic alkem Amgen Amneal AstraZeneca bayer biocon Biogen BioNTech Bristol Myers Squibb cipla covid Daiichi Sankyo drreddy Eli Lilly fda Gilead glenmark gsk Incyte Janssen Jubilant lupin MHRA Moderna Natco Novartis Novavax novo nordisk oncology Panacea Biotech Pfizer pharmacy Pharma News Pharmareg News Remdesivir roche sanofi Sun pharma Teva usfda Vaccine Viatris zydus

Contact us

Address:Pharma Reg News, First floor, Shop no.1 , Plot no 241,242, Near Fire station, GIDC, Ankleshwar, Gujarat - 393002.
Phone:+91 8511586232, +91 9029066605
Email:author@pharmaregnews.com

Browse by Tag

Abbott Alembic alkem Amgen Amneal AstraZeneca bayer biocon Biogen BioNTech Bristol Myers Squibb cipla covid Daiichi Sankyo drreddy Eli Lilly fda Gilead glenmark gsk Incyte Janssen Jubilant lupin MHRA Moderna Natco Novartis Novavax novo nordisk oncology Panacea Biotech Pfizer pharmacy Pharma News Pharmareg News Remdesivir roche sanofi Sun pharma Teva usfda Vaccine Viatris zydus

Advertise with us

© 2021 - Pharmaregnews.com. Developed by YESWEUS.

No Result
View All Result
  • Home
  • Indian Pharma News
  • Global Pharma News
  • Guideline News
    • EMA
    • MHRA
    • TGA
    • US FDA
  • Articles
  • Interview
  • Company Focus
  • Pharma Jobs
    • Quality
    • Regulatory Affairs
    • Production
    • Sales and Marketing
    • bioanalytical
    • Clinical
  • Webinar
  • Contact us
  • Advertise with us
  • Login

© 2021 - Pharmaregnews.com. Developed by YESWEUS.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?